GlobeNewswire

Ether Capital Co-Founder Michael Conn Joins AXEL as Chief Strategy Officer

Dela

Former CEO and Co-Founder of Ether Capital brings a successful track record in finance, blockchain and cryptocurrency

 

LAS VEGAS, July 30, 2018 (GLOBE NEWSWIRE) -- AXEL, the award winning technology company providing users with true ownership and protection over their digital data and content, is pleased to announce the appointment of Michael Conn to the role of Chief Strategy Officer (CSO), effective immediately. Michael will help lead the efforts in the company's upcoming launch of AXEL Token and development of its proprietary blockchain platform.

"We're excited Michael is joining our growing team at AXEL. His years of experience and knowledge in the financial industry, as well as expertise in blockchain and cryptocurrency will be extremely valuable as we launch our own blockchain venture," notes Ben Ow, President and CTO of AXEL. "We consider ourselves a leader in the privacy and security world with our flagship file sharing app that's already enjoyed by millions of people globally. Our next step is to take on the content selling world with our AXEL Token and AXEL Marketplace, and Michael will be a huge part of this initiative, given his background and knowledge of this sector. We're all looking forward to working with him." 

Michael Conn has been at the forefront of the blockchain and crypto space for many years. After serving in senior executive roles with a variety of financial institutions including AllianceBernstein and The TCW Group, Michael founded Quail Creek Partners, and also co-founded and served as CEO of Ether Capital. Ether Capital was the first Ethereum-focused publicly traded company and it raised $45 million through a private placement. As Chief Strategy Officer of AXEL, he will be responsible for advancing interest in the institutional blockchain and crypto community and overseeing the upcoming Token Generation Event (TGE), as well as the future growth of the AXEL Token.

"I couldn't be more excited to join the AXEL team as they launch this exciting business," said Mr. Conn. "You don't always get the opportunity to be part of a truly disruptive endeavour, and I can't wait to get started and work with this wonderful team, and contribute to enhancing AXEL's foothold on the market."

The decision to hire Mr. Conn came after an extensive search by AXEL's principals to find the ideal candidate for this position. He comes highly recommended, and with an impeccable reputation for the successful results he has achieved in previous roles.

About AXEL
Since 2012, AXEL has been committed to providing users with true ownership over their data with dynamic, easy-to-use, patented technology solutions for file sharing, access, security and privacy, transfer, streaming and integration, from one secure platform.

With operations in North America, Europe and Asia, the company's veteran 100+ member team has built a suite of proprietary software products already used by millions of people, with patented technology and a user-friendly app that works across Windows, Mac, iOS and Android.

The AXEL platform allows users to link all digital content across all of their devices, without using a third-party. With additional patents on decentralized access and private sharing capabilities, AXEL's Tack App and AXEL Pay enable users to control and monetize their digital content. The AXEL Marketplace, powered by a dual public and private chain, will complete this decentralized ecosystem, making it a secure, trusted peer-to-peer environment.

For more information, please visit https://www.axeltoken.com and www.axel.org.

Media Contacts
Vsem Yenovkian, AXEL
media@axel.org
702-948-9770

Roberta Tsang, RTPR 
roberta@rtprcomm.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AXEL via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum